ADP-Ribosylation Factor 6 Pathway Acts as a Key Executor of Mesenchymal Tumor Plasticity.

Int J Mol Sci · 2023 · PMC10573442 · PMID 37834383

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might be significantno p-value reported

This suggests that the EGFR-GEP100-ARF6 pathway might be significant in the process of acquiring a malignant phenotype in breast cancer cells.

also in 2,457 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.